Given the high and near ubiquitous expression of DLK1 in ACC, we next sought to determine if DLK1 could be targeted in ACC using a DLK1-directed antibody-drug conjugate (ADCT-701)10,18. This evidence concerns the gene DLK1 and adrenal cortex carcinoma.